MET receptor in oncology: From biomarker to therapeutic target.
Cancer biology
History
MET
Mechanisms
Resistance
Therapeutics
Journal
Advances in cancer research
ISSN: 2162-5557
Titre abrégé: Adv Cancer Res
Pays: United States
ID NLM: 0370416
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
29
6
2020
pubmed:
1
7
2020
medline:
2
10
2020
Statut:
ppublish
Résumé
First discovered in the 1984, the MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor or HGF (also known as scatter factor or SF) are implicated as key players in tumor cell migration, proliferation, and invasion in a variety of cancers. This pathway also plays a key role during embryogenesis in the development of muscular and nervous structures. High expression of the MET receptor has been shown to correlate with poor prognosis and resistance to therapy. MET exon 14 splicing variants, initially identified by us in lung cancer, is actionable through various tyrosine kinase inhibitors (TKIs). For this reason, this pathway is of interest as a therapeutic target. In this chapter we will be discussing the history of MET, the genetics of this RTK, and give some background on the receptor biology. Furthermore, we will discuss directed therapeutics, mechanisms of resistance, and the future of MET as a therapeutic target.
Identifiants
pubmed: 32593403
pii: S0065-230X(20)30038-5
doi: 10.1016/bs.acr.2020.04.006
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
259-301Informations de copyright
© 2020 Elsevier Inc. All rights reserved.